Cargando…

Autophagy inhibition enhances PD-L1 expression in gastric cancer

BACKGROUND: Autophagy, a process for degrading intracellular substances to maintain basal metabolic turnover, is known to be perturbed in gastric cancer. Programmed cell death-1 (PD-1) with its ligand (PD-L1) are important immune checkpoint proteins and their regulation by autophagy has been reporte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Xiaojuan, Wu, William K. K., Gao, Jing, Li, Zhongwu, Dong, Bin, Lin, Xiaoting, Li, Yilin, Li, Yanyan, Gong, Jifang, Qi, Changsong, Peng, Zhi, Yu, Jun, Shen, Lin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440013/ https://www.ncbi.nlm.nih.gov/pubmed/30925913 http://dx.doi.org/10.1186/s13046-019-1148-5

Ejemplares similares

Targeting autophagy potentiates antitumor activity of Met-TKIs against Met-amplified gastric cancer
por: Lin, Xiaoting, et al.
Publicado: (2019)

Intratumoral KIT mutational heterogeneity and recurrent KIT/ PDGFRA mutations in KIT/PDGFRA wild-type gastrointestinal stromal tumors
por: Gao, Jing, et al.
Publicado: (2016)

Association of Lymphocyte-to-Monocyte Ratio With Survival in Advanced Gastric Cancer Patients Treated With Immune Checkpoint Inhibitor
por: Chen, Yang, et al.
Publicado: (2021)

Appropriate PD-L1 Cutoff Value for Gastric Cancer Immunotherapy: A Systematic Review and Meta-Analysis
por: Xie, Tong, et al.
Publicado: (2021)

From AVATAR Mice to Patients: RC48-ADC Exerted Promising Efficacy in Advanced Gastric Cancer With HER2 Expression
por: Chen, Zuhua, et al.
Publicado: (2022)

Positive Status of Epstein-Barr Virus as a Biomarker for Gastric Cancer Immunotherapy: A Prospective Observational Study
por: Xie, Tong, et al.
Publicado: (2020)

Dynamic monitoring of circulating tumour cells to evaluate therapeutic efficacy in advanced gastric cancer
por: Li, Yilin, et al.
Publicado: (2016)

The Inconsistent and Inadequate Reporting Of Immune‐Related Adverse Events in PD‐1/PD‐L1 Inhibitors: A Systematic Review of Randomized Controlled Clinical Trials
por: Xie, Tong, et al.
Publicado: (2021)

Clinicopathological Characteristics and Response to Chemotherapy in Treatment-Naive Epstein–Barr Virus Associated Gastric Cancer: A Retrospective Study
por: Xie, Tong, et al.
Publicado: (2021)

Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer
por: Jia, Keren, et al.
Publicado: (2022)

Correction: Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer
por: Jia, Keren, et al.
Publicado: (2023)

Clinicopathologic and Molecular Features of Colorectal Adenocarcinoma with Signet-Ring Cell Component
por: Wei, Qing, et al.
Publicado: (2016)

Significance of Detection of the HER2 Gene and PD-1/PD-L1 in Gastric Cancer
por: Yun, Tian, et al.
Publicado: (2020)

M1-like TAMs are required for the efficacy of PD-L1/PD-1 blockades in gastric cancer
por: Zhao, Rui, et al.
Publicado: (2020)

Establishment and characterization of patient-derived tumor xenograft using gastroscopic biopsies in gastric cancer
por: Zhu, Yan, et al.
Publicado: (2015)

Activated Wnt signaling promotes growth and progression of AFP-producing gastric cancer in preclinical models
por: Chen, Dongshao, et al.
Publicado: (2019)

Wee1 Inhibitor AZD1775 Combined with Cisplatin Potentiates Anticancer Activity against Gastric Cancer by Increasing DNA Damage and Cell Apoptosis
por: Chen, Dongshao, et al.
Publicado: (2018)

Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint
por: Lin, Xiaoting, et al.
Publicado: (2018)

Expression and clinical significance of c-Met in advanced esophageal squamous cell carcinoma
por: Xu, Yingying, et al.
Publicado: (2015)

Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer
por: Wang, Zhenghang, et al.
Publicado: (2022)

Clinicopathological features of tumor mutation burden, Epstein-Barr virus infection, microsatellite instability and PD-L1 status in Chinese patients with gastric cancer
por: Zhang, Li, et al.
Publicado: (2021)

Aneuploidy of chromosome 8 in circulating tumor cells correlates with prognosis in patients with advanced gastric cancer
por: Li, Yilin, et al.
Publicado: (2016)

Predicting response to immunotherapy in gastric cancer via multi-dimensional analyses of the tumour immune microenvironment
por: Chen, Yang, et al.
Publicado: (2022)

Reduced m6A modification predicts malignant phenotypes and augmented Wnt/PI3K‐Akt signaling in gastric cancer
por: Zhang, Cheng, et al.
Publicado: (2019)

Prediction of immune checkpoint inhibition with immune oncology-related gene expression in gastrointestinal cancer using a machine learning classifier
por: Lu, Zhihao, et al.
Publicado: (2020)

Clinical significance of phenotyping and karyotyping of circulating tumor cells in patients with advanced gastric cancer
por: Li, Yilin, et al.
Publicado: (2014)

High‐affinity PD‐1 molecules deliver improved interaction with PD‐L1 and PD‐L2
por: Li, Yanyan, et al.
Publicado: (2018)

Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors
por: Wang, Haiyue, et al.
Publicado: (2018)

Prognostic Significance of MET Amplification and Expression in Gastric Cancer: A Systematic Review with Meta-Analysis
por: Peng, Zhi, et al.
Publicado: (2014)

CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer
por: Qi, Changsong, et al.
Publicado: (2023)

Co-Expression with Membrane CMTM6/4 on Tumor Epithelium Enhances the Prediction Value of PD-L1 on Anti-PD-1/L1 Therapeutic Efficacy in Gastric Adenocarcinoma
por: Wang, Ziqi, et al.
Publicado: (2021)

PD-L1 and PD-1 expression are correlated with distinctive clinicopathological features in papillary thyroid carcinoma
por: Bai, Yanhua, et al.
Publicado: (2017)

IFN-γ surmounts PD-L1/PD1 inhibition to CAR-T cell therapy by upregulating ICAM-1 on tumor cells
por: Dong, E, et al.
Publicado: (2021)

The Predictive Value of PD-L1 Expression Level in Evaluating the Cost-Effectiveness of Atezolizumab/Pembrolizumab
por: Lin, Shen, et al.
Publicado: (2022)

Pyrotinib combined with CDK4/6 inhibitor in HER2‐positive metastatic gastric cancer: A promising strategy from AVATAR mouse to patients
por: Chen, Zuhua, et al.
Publicado: (2020)

Prognostic Significance of PD-L1 Expression in Gastric Cancer Patients with Peritoneal Metastasis
por: Chen, Xiao-Jiang, et al.
Publicado: (2023)

Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer
por: Zhu, Yan, et al.
Publicado: (2015)

Immune checkpoint inhibitors for treatment of advanced gastric or gastroesophageal junction cancer: Current evidence and future perspectives
por: Zhang, Zhening, et al.
Publicado: (2020)

Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics
por: Zhang, Jie, et al.
Publicado: (2015)

Profiles of PD-1, PD-L1, PD-L2 in Gastric Cancer and Their Relation with Mutation, Immune Infiltration, and Survival
por: Liu, Jingwei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8d7k8q5f11442cu2e2ve66mam3